Ken Griffin Arbutus Biopharma Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $18,096 - $26,447	5,800 Added 19.4%	35,700 $137,000
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $193,536 - $278,784	-76,800 Reduced 71.98%	29,900 $92,000
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $185,093 - $239,148	81,900 Added 330.24%	106,700 $275,000
Q4 2023 Feb 14, 2024	BUY	$1.69 - $2.54 $2,704 - $4,064	1,600 Added 6.9%	24,800 $62,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $1,900 - $2,270	-1,000 Reduced 4.13%	23,200 $47,000
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $27,104 - $37,026	12,100 Added 100.0%	24,200 $55,000
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $122,873 - $170,810	-55,100 Reduced 81.99%	12,100 $36,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $30,178 - $45,030	15,800 Added 30.74%	67,200 $156,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $25,192 - $38,592	-13,400 Reduced 20.68%	51,400 $98,000

156

99.6M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $511M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.